Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received a stock grant as part of her board compensation. On May 29, 2026, she acquired 1,262 shares of common stock valued at $8.91 per share. The filing states these shares were issued in lieu of a quarterly cash board member retainer of $11,250.
After this award, Milne directly holds 16,644 shares of BioCryst common stock. This is a routine, non-market transaction reflecting compensation paid in equity instead of cash, rather than an open-market purchase or sale.
Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported receiving 631 shares of Common Stock on May 29, 2026. These shares were issued in lieu of 50% of his quarterly Board member cash retainer of $11,250 at a price of $8.91 per share.
After this stock-based retainer, Stonehouse directly holds 1,324,481 shares of Common Stock. The filing also lists 40,000 shares held in the Samuel Stonehouse Irrevocable Trust and 40,000 shares in the Caroline Stonehouse Irrevocable Trust, reported as indirect ownership through his wife as co‑trustee.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving a grant of 631 shares of Common Stock on May 29, 2026 at a reference price of $8.91 per share. The shares were issued to her in lieu of 50% of a quarterly Board member cash retainer of $11,250. Following this compensation-related award, she directly holds 31,883 shares of the company’s Common Stock.
MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported receiving 1,122 shares of Common Stock on May 29, 2026. These shares were granted as compensation, issued in lieu of 50% of his quarterly cash Board Chair retainer of $20,000. After this grant, he directly holds 93,189 shares of the company’s common stock. This is a routine, non-market award rather than an open-market purchase.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received a stock award instead of cash compensation. He was granted 1,262 shares of common stock at a reference value of $8.91 per share on May 29, 2026, issued in lieu of a $11,250 quarterly board cash retainer. After this grant, he directly holds 20,165 shares of BIOCRYST common stock. This is a routine, compensation-related equity award rather than an open-market purchase.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee sold 11,180 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $8.97 per share, with individual trade prices ranging from $8.96 to $8.985. Following the sale, she directly holds 31,252 shares of the company’s stock.
BCRX files a Form 144 notice to sell 11,180 shares of Common Stock. The filing lists two stock-plan-related dispositions: 4,360 shares dated 06/07/2023 and 6,820 shares dated 06/12/2025. The broker shown is Merrill Lynch and the excerpt lists 254,162,660 shares outstanding as of 05/18/2026.
BIOCRYST PHARMACEUTICALS INC Chief Legal Officer Alane P. Barnes exercised employee stock options for 62,500 shares of common stock at $5.04 per share and sold 62,500 shares in an open-market transaction at $9.54 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan and is described as automatic, rather than a discretionary trade. After these transactions, Barnes directly holds 400,703 shares of Biocryst common stock.
BCRX reported a Form 144 registering the resale of 62,500 shares of Common Stock for sale on 05/13/2026. The filing lists the sale method as cash and references an option granted 12/20/2017 as the source of the shares. The filing also records a prior sale of 150,000 shares on 03/16/2026 for $1,372,013.10.
State Street Corporation reported beneficial ownership of 12,208,360 shares of BioCryst Pharmaceuticals common stock, representing 4.9% of the class as of 03/31/2026. The filing shows 11,618,245 shares with shared voting power and 12,208,360 shares with shared dispositive power.